Cue Biopharma (CUE) Non Operating Income (2018 - 2025)

Cue Biopharma has disclosed Non Operating Income across 8 years of filings, most recently posting $107000.0 for Q4 2025.

• Non Operating Income for Q4 2025 came in at $107000.0, down 21.9% year-over-year; the trailing twelve-month figure through Dec 2025 was $449000.0 (down 45.58% YoY), and the FY2025 annual result was $450000.0, down 45.52% from the prior year.
• Non Operating Income came in at $107000.0 for Q4 2025 at Cue Biopharma, down from $147000.0 in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $414000.0 in Q3 2023 to a low of -$118000.0 in Q2 2022.
• The 5-year median for Non Operating Income is $142000.0 (2024), against an average of $148494.9.
• Peak annual rise in Non Operating Income reached 6929.25% in 2022, while the deepest fall reached 591.67% in 2022.
• Cue Biopharma's Non Operating Income stood at $3898.0 in 2021, then soared by 6929.25% to $274000.0 in 2022, then surged by 45.26% to $398000.0 in 2023, then tumbled by 65.58% to $137000.0 in 2024, then retreated by 21.9% to $107000.0 in 2025.
• The last three Non Operating Income figures came in at $107000.0 (Q4 2025), $147000.0 (Q3 2025), and $153000.0 (Q2 2025), per Business Quant data.